Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Issue 4 (1st November 2013)
- Record Type:
- Journal Article
- Title:
- Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Issue 4 (1st November 2013)
- Main Title:
- Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma
- Authors:
- Bass, Johnnie K.
Huang, Jie
Onar‐Thomas, Arzu
Chang, Kay W.
Bhagat, Shaum P.
Chintagumpala, Murali
Bartels, Ute
Gururangan, Sridharan
Hassall, Tim
Heath, John A.
McCowage, Geoffrey
Cohn, Richard J.
Fisher, Michael J.
Robinson, Giles
Broniscer, Alberto
Gajjar, Amar
Gurney, James G. - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24830-sec-0001" sec-type="section"> <title>Background</title> <p>Reporting ototoxicity is frequently complicated by use of various ototoxicity criteria. The International Society of Pediatric Oncology (SIOP) ototoxicity grading scale was recently proposed for standardized use in reporting hearing loss outcomes across institutions. The aim of this study was to evaluate the concordance between the Chang and SIOP ototoxicity grading scales. Differences between the two scales were identified and the implications these differences may have in the clinical setting were discussed.</p> </sec> <sec id="pbc24830-sec-0002" sec-type="section"> <title>Procedures</title> <p>Audiological evaluations were reviewed for 379 patients with newly diagnosed medulloblastoma (ages 3–21 years). Each patient was enrolled on one of two St. Jude clinical protocols that included craniospinal radiation therapy and four courses of 75 mg/m<sup>2</sup> cisplatin chemotherapy. The latest audiogram conducted 5.5–24.5 months post‐protocol treatment initiation was graded using the Chang and SIOP ototoxicity criteria. Clinically significant hearing loss was defined as Chang grade ≥2a and SIOP ≥2. Hearing loss was considered serious (requiring a hearing aid) at the level of Chang grade ≥2b and SIOP ≥3.</p> </sec> <sec id="pbc24830-sec-0003" sec-type="section"> <title>Results</title> <p>A strong concordance was observed between the<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24830-sec-0001" sec-type="section"> <title>Background</title> <p>Reporting ototoxicity is frequently complicated by use of various ototoxicity criteria. The International Society of Pediatric Oncology (SIOP) ototoxicity grading scale was recently proposed for standardized use in reporting hearing loss outcomes across institutions. The aim of this study was to evaluate the concordance between the Chang and SIOP ototoxicity grading scales. Differences between the two scales were identified and the implications these differences may have in the clinical setting were discussed.</p> </sec> <sec id="pbc24830-sec-0002" sec-type="section"> <title>Procedures</title> <p>Audiological evaluations were reviewed for 379 patients with newly diagnosed medulloblastoma (ages 3–21 years). Each patient was enrolled on one of two St. Jude clinical protocols that included craniospinal radiation therapy and four courses of 75 mg/m<sup>2</sup> cisplatin chemotherapy. The latest audiogram conducted 5.5–24.5 months post‐protocol treatment initiation was graded using the Chang and SIOP ototoxicity criteria. Clinically significant hearing loss was defined as Chang grade ≥2a and SIOP ≥2. Hearing loss was considered serious (requiring a hearing aid) at the level of Chang grade ≥2b and SIOP ≥3.</p> </sec> <sec id="pbc24830-sec-0003" sec-type="section"> <title>Results</title> <p>A strong concordance was observed between the Chang and SIOP ototoxicity scales (Stuart's tau‐c statistic = 0.89, 95% CI: 0.86, 0.91). Among those patients diagnosed with serious hearing loss, the two scales were in good agreement. However, the scales deviated from one another in classifying patients with less serious or no hearing loss.</p> </sec> <sec id="pbc24830-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Although discrepancies between the Chang and SIOP ototoxicity scales exist primarily for patients with no or minimal hearing loss, the scales share a strong concordance overall. Pediatr Blood Cancer 2014;61:601–605. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Pediatric blood & cancer. Volume 61:Issue 4(2014:Apr.)
- Journal:
- Pediatric blood & cancer
- Issue:
- Volume 61:Issue 4(2014:Apr.)
- Issue Display:
- Volume 61, Issue 4 (2014)
- Year:
- 2014
- Volume:
- 61
- Issue:
- 4
- Issue Sort Value:
- 2014-0061-0004-0000
- Page Start:
- 601
- Page End:
- 605
- Publication Date:
- 2013-11-01
- Subjects:
- Tumors in children -- Periodicals
Blood -- Diseases -- Periodicals
Cancer in children -- Periodicals
618.92 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/pbc.24830 ↗
- Languages:
- English
- ISSNs:
- 1545-5009
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6417.533500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3561.xml